Peter Thiel-backed Lindus Health has raised $55 million as it sets about "fixing the broken clinical trial industry." ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a biotechnology company focused on developing novel therapies for RAS-dependent cancers, has been garnering significant attention from analysts and investors ...

Challenges persist, as the clinical research sector can be slow to adopt these innovations. Comprehensive evidence and ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...

The phage therapy market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant infections and the growing interest in alternative treatments. Advances in ...

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

From our point of view, Bioxtran is a highly undervalued asset with exceptionally strong clinical trial data that warrants further development. We are very happy to provide the capital needed to ...

Kyverna Therapeutics (KYTX) announced the appointment of Naji Gehchan, to Chief Medical and Development Officer, where he will lead the ...

An experimental blood test for pancreatic cancer is being evaluated by a commercial laboratory, an important milestone toward ...

UofL was recently awarded its largest clinical research investment in the institution's history with $11.7 million from the ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...